Syndax Pharmaceuticals Inc. (SNDX) - Q3 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2025. Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on cancer therapies. The company currently has two FDA-approved products: Revuforj (revumenib), a menin inhibitor for acute leukemia, and Niktimvo (axatilimab-csfr), a CSF-1R blocking antibody for chronic graft-versus-host disease (cGVHD), which is co-commercialized with Incyte Corporation.
Key Financial Metrics (Nine Months Ended Sept 30, 2025)
| Metric | Value (in millions) |
|---|---|
| Total Revenue | $103.6 |
| - Product Revenue (Revuforj) | $80.6 |
| - Collaboration Revenue (Niktimvo) | $23.0 |
| Net Loss | $(217.4) |
| Operating Expenses | $314.2 |
| - R&D Expenses | $180.1 |
| - SG&A Expenses | $129.8 |
| Cash & Investments | $456.1 |
| Debt (Royalty Financing) | $343.9 (Net Liability) |
| Accumulated Deficit | $(1,438.6) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased by $87.6 million (548%) compared to the nine months ended September 30, 2024. This is driven by the commercial launch of Revuforj (approved Nov 2024) and Niktimvo (approved Aug 2024), whereas the prior year had no product revenue.
- Expense Increases: SG&A expenses rose by $46.6 million year-over-year due to commercialization costs for the two new products. R&D expenses increased slightly by $4.0 million, despite a $15.0 million milestone payment in the prior year, due to ongoing clinical trials.
- Debt Financing: The company incurred significant royalty interest expense ($24.2 million for the nine months) related to a $350 million royalty financing agreement with Royalty Pharma entered into in November 2024.
- Inventory Build: Inventory increased from $0.4 million to $25.0 million as the company capitalized costs for commercial manufacturing of Revuforj.
Outlook, Risks, and Unusual Items
- Recent Approval: On October 24, 2025 (subsequent to the period end), the FDA approved Revuforj for a second indication: relapsed/refractory AML with NPM1 mutations. This triggered a $7.0 million milestone expense payable to AbbVie.
- Liquidity: Management believes current cash, investments ($456.1 million), and expected product revenue are sufficient to fund operations for the foreseeable future. The company has an At-The-Market (ATM) equity program with $157.9 million remaining capacity.
- Risks: Key risks include the uncertainty of clinical trial outcomes for pipeline candidates, competition in the cGVHD and AML markets, and the impact of the ongoing U.S. government shutdown (started Oct 1, 2025) on FDA review timelines.
- Unusual Items: The company recorded a full reserve against a $3.7 million receivable from Eddingpharm related to entinostat milestones in China, recognizing it as an SG&A expense.
Investor Verification Checklist
- Verify the commercial uptake trajectory of Revuforj and Niktimvo given the rapid revenue ramp-up in Q3 2025.
- Monitor the impact of the $350 million Royalty Pharma financing on future cash flows, specifically the 13.8% royalty rate on U.S. Niktimvo sales.
- Assess the timeline and data readouts for the Phase 3 EVOLVE-2 trial (Revuforj in frontline AML) and the Phase 3 cGVHD trial for Niktimvo.
- Review the status of the $3.7 million Eddingpharm receivable and the likelihood of collection despite the reserve.
- Track the impact of the October 2025 government shutdown on the FDA's ability to process the supplemental NDA for Revuforj's second indication.